Featured Publications
Expression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original ResearchDendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma
Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, Xu ML. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2018, 26: e101-e106. PMID: 29189264, DOI: 10.1097/pai.0000000000000615.Peer-Reviewed Original ResearchConceptsPrimary mediastinal large B-cell lymphomaMediastinal gray zone lymphomaClassic Hodgkin lymphomaGray zone lymphomaPD-L1Mediastinal large B-cell lymphomaLarge B-cell lymphomaDendritic cell markersB-cell lymphomaCell gene expression profilesHodgkin's lymphomaRare entityCD123LymphomaTherapeutic potentialCell markersTherapeutic significanceGenetic featuresGene expression profilesFascinRepresentative sectionsExpression profilesImmunohistochemistryTumorsDiagnosis
2022
Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.
Gru AA, Lim MS, Dogan A, Horwitz SM, Delabie J, Fu K, Peker D, Reddy VVB, Xu ML, Vij K, Slack GW, Miranda RN, Jagadeesh D, Lisano JM, Hsi ED, Torlakovic E. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives Of Pathology & Laboratory Medicine 2022, 147: 79-86. PMID: 35472771, DOI: 10.5858/arpa.2021-0270-oa.Peer-Reviewed Original ResearchMeSH KeywordsConsensusHodgkin DiseaseHumansImmunohistochemistryKi-1 AntigenLymphoma, T-Cell, PeripheralConceptsCD30 expressionPeripheral T-cell lymphomaClassic Hodgkin lymphomaT-cell lymphomaDifferential diagnostic considerationsHematologists/oncologistsExpert panel consensusCD30 positivityHodgkin's lymphomaPredictive biomarkersDiagnostic workupImmunohistochemistry testingLymphoma biopsiesTherapeutic decisionsDiagnostic considerationsCD30 immunohistochemistryConsensus recommendationsPanel consensusLymphomaPositive expressionBest practice recommendationsImmunohistochemistryTumor cellsPractice recommendationsPanel recommendationsIRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas
McQuaid DC, Katz SG, Xu ML. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. American Journal Of Clinical Pathology 2022, 158: 173-176. PMID: 35460405, PMCID: PMC10664184, DOI: 10.1093/ajcp/aqac044.Peer-Reviewed Original Research
2021
Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients
Gru AA, Bacchi CE, Pulitzer M, Bhagat G, Kempf W, Robson A, Plaza JA, Pincus L, Raghavan S, Xu M, da Silva T, Salavaggione AL, Subtil A, Battistella M. Secondary skin involvement in classic Hodgkin lymphoma: Results of an international collaborative cutaneous lymphoma working group study of 25 patients. Journal Of Cutaneous Pathology 2021, 48: 1367-1378. PMID: 34089205, PMCID: PMC9555338, DOI: 10.1111/cup.14077.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overFemaleHodgkin DiseaseHumansMaleMiddle AgedRetrospective StudiesSkin NeoplasmsConceptsClassic Hodgkin lymphomaSecondary skin involvementHodgkin's lymphomaCutaneous involvementSkin involvementComprehensive histopathologic evaluationStage IV diseaseNodular sclerosis typeLarge case seriesBoard-certified dermatopathologistClassic HLSkin disseminationMixed cellularityMost patientsCase seriesSclerosis typeImmunophenotypic featuresInfiltrative plaquesFirst diagnosisHistopathologic evaluationMultiple lesionsSkin lesionsSingle lesionLarge seriesClinical diagnosis
2013
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research 2013, 19: 3462-3473. PMID: 23674495, PMCID: PMC4102335, DOI: 10.1158/1078-0432.ccr-13-0855.Peer-Reviewed Original ResearchConceptsDiffuse large B-cell lymphomaAggressive B-cell lymphomasB-cell lymphomaPosttransplant lymphoproliferative disorderClassical Hodgkin lymphomaLarge B-cell lymphomaPD-L1Hodgkin's lymphomaT-cell/histiocyte-rich B-cell lymphomaExtranodal NK/T-cell lymphomaTissue biopsiesEBV-positive posttransplant lymphoproliferative disordersHistiocyte-rich B-cell lymphomaPD-1/PD-L1 pathwayNK/T-cell lymphomaPD-1/PD-L1Primary mediastinal large B-cell lymphomaNodular lymphocyte predominant Hodgkin lymphomaMixed cellularity classical Hodgkin lymphomaMediastinal large B-cell lymphomaCell death ligand 1Lymphocyte predominant Hodgkin lymphomaPD-L1 protein expressionPD-L1 expressionPD-L1 pathway